Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by InnoCare Pharma
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
March 28, 2024
From
InnoCare Pharma
Via
Business Wire
InnoCare Releases 2023 Results and Business Highlights
March 28, 2024
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
March 12, 2024
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China
January 23, 2024
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
January 16, 2024
From
InnoCare Pharma
Via
Business Wire
InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Appoints Xin Fu as Chief Financial Officer
December 17, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis
December 17, 2023
From
InnoCare Pharma
Via
Business Wire
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH
December 10, 2023
From
InnoCare Pharma
Via
Business Wire
10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH
November 14, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China
October 26, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib
September 13, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Releases 2023 Interim Results and Business Highlights
August 29, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China
July 25, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China
July 04, 2023
From
InnoCare Pharma
Via
Business Wire
Latest Data of InnoCare’s Orelabrutinib Presented at the 17th International Conference on Malignant Lymphoma (ICML)
June 15, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL
April 19, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Subject Dosed in Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China
April 03, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Releases 2022 Annual Results and Business Highlights
March 27, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China
March 09, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05
February 23, 2023
From
InnoCare Pharma
Via
Business Wire
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology
February 06, 2023
From
InnoCare Pharma
Via
Business Wire
Latest Clinical Data of InnoCare’s Gunagratinib Presented at 2023 ASCO GI
January 25, 2023
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of Tafasitamab in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
December 27, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
December 20, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore
November 22, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales
November 13, 2022
From
InnoCare Pharma
Via
Business Wire
10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH
November 07, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China
October 31, 2022
From
InnoCare Pharma
Via
Business Wire
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
September 20, 2022
From
InnoCare Pharma
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.